Area Innovazione e Formazione

 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi Area Innovazione e Formazione
Elenco punti incontro
Pag. 2
Schede partecipanti
Pag. 3
Connecting Universities
Universities, Start-up and Spin-off show their technological
innovations to the industry
Workshop
Pag. 20
1 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi TEFARCO Innova, Consorzio interuniversitario Nazionale di Tecnologie Farmaceutiche Innovative
(Universities of: CT, BO, FE, MO, NA, PR, PV, PG, SA, SI, SS, TO)
email: [email protected]
CENTRI-SPIN-OFF-STARTUP
APTSol – Spin-off - Università Piemonte Orientale NOVARA
Dott. Andrea Foglio Bonda – email: [email protected]
AQUILON PHARMACEUTICALS Ulg – Spin-off University of LIEGI (F)
Prof. Paul Maes – email: [email protected]
BEENEXT Spin-off - Università di TORINO
Prof. Franco Dosio – email: [email protected]
BIOPHARMANET-TEC – Centro interdipartimentale - Università di PARMA
Prof. Ruggero Bettini – email: [email protected]
CHT - CENTER FOR HEALTH TECNOLOGIES - Università di PAVIA
Ing Riccardo Bellazzi – Prof.ssa Bice Conti – email [email protected]
DOME MATRIX – Startup in foundation – Università di PARMA
Dr.ssa Giulia Pasotti – email: [email protected]
ETICHUB – Academic Spin off- Università di PAVIA
Dr.ssa Mariella Bleve email: [email protected]
PHARMAFILM srl – Spin-off - Università di MILANO
Dr. Francesco Cilurzo – email: [email protected]
PLUME STARS srl- Startup - Università di PARMA
Dott.ssa Annagiulia Balducci – email: [email protected]
POLYMERIX – Startup innovativa – Università di PAVIA
Dr.ssa Sofia Giorgetti – email: [email protected]
UNIVERSITA’
Università di BOLOGNA - Dipartimento di Farmacia e Biotecnologie
Prof.ssa Nadia Passerini – email: [email protected]
University of BONN - Pharmazeutische Technologie- Rheinische-Friedrich-Wilhelms-Universität Bonn
Prof. Dr. Karl G. Wagner – email: [email protected]
Università di PADOVA: Dipartimento Scienze del Farmaco
Prof. Nicola Realdon – email: [email protected]
Università di ROMA LA SAPIENZA: Dipartimento di Chimica e Tecnologia del Farmaco
Prof. Pietro Matricardi – email: [email protected]
Università di PAVIA: Department of Drug Sciences
Prof.ssa Carla Caramella – email: [email protected]
Università di PISA: Dipartimento di Farmacia
Prof. Patrizia Chetoni – email: [email protected]
2 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi CONSORZIO TEFARCO Innova
NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
TEFARCO Innova
Consorzio Interuniversitario Nazionale di Tecnologie Frarmaceutiche
Innovative
http://www.tefarco.it
Consortium of Italian Universities
Universities: Bologna, Catania, Ferrara, Modena, Napoli, Parma, Pavia,
Perugia, Salerno, Sassari, Siena, Torino
Area delle Scienze 27/ a, c/o Dip.to Farmacia
43124 Parma
Tel 0521.905073, fax 0521.905006
email [email protected]
The Interuniversity Consortium for Innovative Pharmaceutical Technologies, TEFARCO Innova, is an
institution
for
research
and
advanced
education
in
health
product
technologies.
Due to the critical mass, TEFARCO is the answer to company multiple needs of development
pharmaceutics, from molecule to medicine, with a focus on drug delivery sciences.
TEFARCO has the structure of liason office able to create contacts between Industries and Universities by
means of contract research, seminars ancd scientific communication, higher education, incubation and
stimulus
for
university
spin-off
to
international
innovative
research
networks.
The partner Univeristies are active on materials, products, delivery device, manufacturing, quality, drug
formulation and regulatory.
The scientific know-how of Consortium partners allows to develop innovative projects in the fields of
health products. In particolar, for pharmaceuticals, the projects includes: matrix or reservoir, for oral
administration or transmucosal absorption; polymeric devices for transdermical administration;
cyclodextrin inclusion compounds for nasal, pulmonary and oral administration; polymeric vectors,
liposomes, solid lipid nanoparticles (SNL), microemulsions for parenteral administration; drug-polymer
conjugates for peptide and protein transport.
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Consorzio Interuniversitario Nazionale di Tecnologie Farmaceutiche
Innovative – TEFARCO Innova
Speaker: Paolo Colombo
3 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi Advanced
Pharmaceutical
Technology
Solutions
NAME of the company or
institution
Web site
Type of society
In case of spin-off, startup,
center, refer the University
Address
Contacts (phone – fax - email)
APTSol. S.r.l.s.
APTSol. S.r.l.s.
www.aptsol.it
Spin-off e Startup innovativa
Università del Piemonte Orientale
Università del Piemonte Orientale
Largo Donegani 2/3,
28100 Novara
Andrea Foglio Bonda (CEO)
[email protected]
(+39) 0321-375862
APTSol is an Organization specialized in the formulation development of dosage forms or production
intermediates. We are specialized in applying innovative technologies to obtain high added-value
formulations. We are able to find the right solution to your formulation issue.
Our knowledge of processes and formulations, together with the availability of advanced instrumentation,
allows us to provide high added-value services that will contribute to the success of your products.
The APTSol team is characterized by a strong academic and professional experience in the formulation
field, and it is able to provide services that range from performing analyses to providing innovative and
effective responses to the problems presented by clients.
Among the most innovative services that APTSol offers, there is micro-encapsulation by different
technologies:
- Spray Drying
- Ionotropic Gelation
- Spray Congealing
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Explore innovative pharmaceutical solution with us
Speaker: Andrea Foglio Bonda
4 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi Aquilon Pharmaceuticals SA and
Liège University
NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
Aquilon Pharmaceuticals SA and Liège University Belgium
www.aquilon.com
Spin-off
University of Liège (ULg)
Rue porte de Lorette 76
4600 Visé Belgium
&
CHU - Tour 4 - Niveau +4 (Bât. B36)
Quartier Hôpital - Avenue Hippocrate, 15
4000 Liège
[email protected]
Aquilon Pharmaceuticals is a Liège University Spin-off (Belgium) created end of 2013. Aquilon has a
unique expertise in the research and the development of active complexes included in HPßCD to enhance
the efficacy of existing drugs or poorly soluble drugs. The first development of Aquilon Pulmonary division
combines HPßCD and a known inhaled corticosteroid.
As classical drugs (topical steroids, bronchodilators…) display a limited effectiveness in many patients, the
active drugs might need to be given at high doses that can reach toxicity threshold, there is room for
improvement.
Cyclodextrins are cyclic oligosaccharides derived from the natural starch forming a hydrophobic cavity. A
specific cyclodextrin (HPßCD) was found to display specific properties.
Aquilon found that there was a synergistic potentiation of the steroids activity, with a longer duration of
action and better safety profile (in phase I) than the drug alone
Aquilon Pharma owns one patent protecting the unique properties of HPßCD (US2015258133 and
US2012295872) , Aquilon has also the exclusive rights for a new Curcumin HPßCD Lysine salt complex
(US 8,772,265) and a PCT has been filed in 2014 protecting the combination HPßCD-inhaled
corticosteroids including budesonide derivatives (WO2015144938).
Aquilon is looking for additional partners at various stages of its development (devices, equipment, Clinical
studies, CMO, Marketing partners)
People & Founding members:
Paul Maes Pharm, (Chairman of the board) – > 15 years’ experience as R&D VP
in different companies in North America. and > 15 years of drug development
and proactive consulting in EU
Didier Cataldo MD, PhD (member of the board) – Pulmonary physician,
research lab director, prof faculty of medicine.
Brigitte Evrard Pharm, PhD – Specialist in pharmaceutical technology, research
lab director, Prof Faculty of medicine.
François Boitquin (member of the board) - >15 years’ experience in finance &
business development.
Scientific board:
Prof. Paolo Colombo (University of Parma)
Prof. Eef Vanderhelst (VUB)
Prof. Wim Janssens (KUL)
Prof. Jean Paul Remon (U Ghent)
Prof. Brigitte Evrard (Ulg)
Prof. Didier Cataldo (Ulg)
Special Member.
Prof Dominique Duchêne (Paris XI)
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Innovative solutions for the treatment of respiratory diseases
Speaker: Paul Maes
5 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi BEENEXT
NAME of the company or
institution
BEENEXT S.r.l.
Web site
Type of society
www.arachnoscience.com – _www.beenext.it
Spin-Off
In case of spin off, start Up,
center, refer the University
Address
Università di Torino - Dipartimento di Scienza e Tecnologia del
Farmaco (DSTF)
Via G. Quarello 15/a 10135 – Torino
Via P. Giuria 9, 10125 - Torino
Tel. +39 011.6706661 – Fax +39 011 6707987 – [email protected]
Contacts (phone – fax - email)
Beenext is a Spin-Off of the University of Turin. It has been created by three members on the Department of Science
and Drug Technology (DSTF) of the University of Turin - UniTO (Italy) and incubated at the 2i3T, the Business
Incubator and Technology Transfer Process at the University of Turin. Starting from its foundation in the late eighties,
DSTF has become a centre of strong expertise in all the aspect of the Drug Design. Beenext was born with the purpose
to move that academic experience to the Drug Design market. The founders DSTF team was then carefully arranged in
order to create a technological complementary platform effective in the design of small entities as early drug candidates.
Involved inside international collaboration with the academic as well as SME words, the extensive use of
ARACHNO™, a proprietary patented-pending technology (Patent n. TO2012A000941), developed to accelerate the
synthetic process, allows our chemists to reach faster the desired target molecules.
Currently operates in three specific fields:
· EDUCATIONAL: Advanced solutions in support of the Experimental Teaching in chemistry / science.
· FINE ACTIVE MOLECULES DESIGN
- Oncology
- Immunosuppression
- Inflammation
· INNOVATIVE SCIENTIFIC GLASSWARE
- Smart glassware
- arachno™ project
ARACHNO™ is a technology that helps chemists to overcome bottlenecks in processes where different operative
conditions have to be evaluated, from organic synthesis to micro-nanoparticles preparation.
As a perfect mix of high tech solution and simplicity, ARACHNO™ is a perfect breakthrough technology. By using an
ARACHNO™ it is possible the stirring under modified atmosphere with any type of gas of up to six reaction mixtures.
The reaction mixture could be cooled or heated and, if needed, could be also concentrated to dryness avoiding the time
consuming multievaporation step.
ARACHNO™ also allows to conduct reactions with different solvents thanks to its expansion chamber that avoid any
cross contamination between reaction vessels.
ARACHNO™ is a patented technology 100% Made in Italy, it is offered in various models suitable for all needs and
fully customizable.
ARACHNO™ was developed in collaboration with leading Italian brands in the world of scientific glassware and
design.
6 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi BIOPHARMANET-TEC
NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
BIOPHARMANET-TEC
http://biopharmanet-tec.it
Interdepartmental Centre for Innovation in Health Products
Università degli Studi di Parma
Dipartimento di Farmacia
Parco Area delle Scienze, 27/a
43124 Parma, Italy
Email: [email protected]
The Centre BIOPHARMANET-TEC is an initiative of University of Parma University to promote, manage
and participate in:
• Industrial research projects
• Specialist training services
• Technology transfer
The Center Biopharmanet-Tec is active in the development of processes for the production of innovative
compounds, drug delivery platforms and in pharmaceutical nanotechnologies.
The technological aims are the Industrial Research and Technology Transfer in the Platform of Life
Sciences, especially for R&D projects related to:
• Pharmaceutical Technology, Drug Delivery
• Pharmaceutical Chemistry, Drug Discovery
• Drug Development
• Experimental Pharmacology and Toxicology
• Pharmaceutical Engineering and Process Technology
• Biochemistry and Molecular Biology, Recombinant DNA Technology
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
BIOPHARMANET TEC – Leading Innovation in Pharma
Speaker: Fabio Sonvico
7 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi Centre of Health Technology
CHT
NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
Centre of Health Technology, University of Pavia
CHT
http://cht.unipv.it/index.php/it/
Interdepartmental research centre
University of Parma
Via Ferrata 5, 27100 Pavia, Italy
[email protected]
The Centre for Health Technology (CHT) of the University of Pavia aims at providing technological
solutions for solving problems in human health, from bench to bedside, by fostering interdisciplinary
research that integrates basic sciences, medicine, pharmaceutics and engineering. The CHT also deals with
legal and ethical issues related to science and technologies applied to human beings and society in a way
that guarantees fundamental rights without hampering technological applications and their benefits.
It currently involves 11 University departments and provides an effective model for fostering a strong
interaction and dialogue between the conceptual models of science and technology in the view of mutual
improvement, taking into account both legal and scientific-technological sides.
The CHT is active in five biomedical areas, including Regenerative medicine and cell therapy, Diagnostics,
Surgery and Prosthetics, Rehabilitation, Personalized Medicine. The research activity is organized through
a horizontal coordination layer and a number of technological and application challenges that is redefined
every three years. For the current period (2015-17), the following key activities will be pursued:
1- Advanced diagnostic instrumentation, including 4D Ultrasound imaging, Multimodal imaging systems
based on millimeter-waves and ultrasound, Nanoparticles for MRI Imaging and Advanced photodetection
techniques for biosensing in micro-opto-fluidic systems.
2- Bio-medical informatics systems for translational medicine, including Big-data enabled methods and
infrastructures, novel distributed decision-support systems, innovative systems for network-biology and
pharmacology.
3- Innovations in tissue engineering and regenerative medicine, including bone, cardiac and ovarian Tissue
Engineering, smart biomaterials, electromagnetic treatments and synthetic Biology.
4- Nano-medicine technology for diagnostics and therapy, including Multitasking Nanoparticles for therapy
and imaging, Surface-intelligent Medical Devices, G-quadruplex (G4), Hydroxyapatite Nanoparticles as a
countermeasure for microgravity related diseases, Bio-characterization.
5- Legal, ethical and socio-technical aspects of new technologies in biomedicine, in collaboration with the
European Centre for Law, Science and New Technologies (ECLT) at the University of Pavia.
Several projects included in the CHT are currently funded by the EU, by NATO, by Foundations and the
Lombardia region.
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Centre for Health Technology
Speaker: Bice Conti
8 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi DOME MATRIX
NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
Dome Matrix
Spin off (in fundation)
University of Parma
Parco Area delle Scienze 27/A, 43124, Parma, Italy
Email: [email protected]
The proponents are four motivated researchers: one post-doc researcher, two assistant professors and one
associate professor sharing the same passion for pharmaceutical research. The four proponents are willing
to found a spin-off based on the module assembling Dome Matrix technology. They work together since
several years at the University of Parma and the University of Ferrara. Dr. Giulia Pasotti is the CEO and she
works on innovative oral delivery systems developing new technologies. Dr. Alessandra Rossi takes care
about logistic, planning and purchasing, Dr. Gaia Colombo is the IP manager and Dr. Fabio Sonvico deals
with investor relations and customer contact.
The company is based on Dome Matrix products, a novel technology platform for oral drug release based
on the assemblage of individual modules. The product is a polypill obtained by the assembling of several
modules containing one or more drugs, assembled in different sequences. The assembled modular system is
the actual administration unit and enables versatility of dosage, combination of two or more drugs, tailored
release kinetics and therapy customization to more effectively fight the disease. Dome Matrix has the
ambition to replace existing oral drug delivery systems. The platform can be applied to various drug
combinations. The global pharmaceutical market has been characterized by a decline of new molecules and
a growing interest in copies of existing medicines (generic) or new forms of administration. A company that
acquires our drug delivery technology can renovate its product portfolio and sell a unique product due to
patent protection. The strategy for the transfer of technology consists of a license for the manufacture and
sale of the product developed for the client company, in exchange for a lump sum due to patent access and
royalties on sale revenues. In alternative, a profit-sharing could be considered in case of direct
manufacturing.
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Dome Matrix
Speaker: Giulia Pasotti
9 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi ETICHUB Srl
NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
EticHub s.r.l.
www.etichub.it
Academic Spin off
University of Pavia
Via Taramelli 12, 27100 Pavia, Italia
+39-0382987193- 388 770 4810- [email protected]
Etichub Srl is the result of the business venture of a research group of the Department of Drug Science,
University of Pavia. It is an academic spin-off that offers advice throughout all the construction process of a
cosmetic product, also through the implementation of innovative solutions.
We offer to the customer different services:
Consulting. Legislative support for the fulfillment of the Cosmetics Regulation 1223/2009 and drafting of
the Product Information File of the finished product.
Efficacy. “In vivo” tests to support the aspects claimed by a product / line following validated protocols or
development of new ones to support specific claim; self-evaluation test on a wide number of panelists;
sensorial analysis.
Safety. “In vitro” and “in vivo” tests to evaluate the safety of raw materials and finished products;
tolerability evaluation even associated to clinical judgement (dermatologist, ophthalmologist, gynecologist,
pediatrician).
Quality. Stability tests to ensure that a product meets the intended physical, chemical and microbiological
quality standards as well as functionality and organoleptic conditions.
Formulation. Development of new innovative cosmetic products adopting a multi-step approach
considering both the end use of the product and the marketing requests. Great focus on natural raw
materials as well as on sustainable methods of production.
Innovation. Application of the protocols and prototypes developed in the academic laboratories,
characterization of the ingredients and application of innovative technologies.
• Development of cosmetic products containing Solid Lipid Nanoparticles
• Formulation of cosmetic products containing byproducts of food industry
• Development of new protocols for the use of the ‘Nail analyzer’ device patented by the University
of Pavia
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Take care of your idea, build your cosmETIC product
Speaker: Camilla Grignani
10 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi PHARMAFILM
NAME of the company or
institution
Web site
Type of society
Address
Contacts (phone – fax - email)
Pharmafilm srl
Spin-off of University of Milan
Strada Vigevanese – Località Barbattola
20083 Gaggiano – MILANO
+390250324635 - +390250324657, [email protected]
Pharmafilm s.r.l. is a spin-off of the University of Milan. The company designs and develops new
technologies to develop therapeutic systems intended for the administration of one or more active
ingredients. To date, three platform have been developed and patented:
- orodispersible films (Malt-O-Fast);
- bioadhesive microparticle suspensions.
- adhesive hydrophilic matrices for the development of transdermal patches or medicated plasters.
Pharmafilm s.r.l. is mainly devoted to demonstrate the feasibility to load active ingredients in its
platforms. However, the industrial scale-up of all the three technologies has been completed and the
first drug product based on Malt-O-Fast technology will be launched on the market in 2017.
Orodisperdible films are dosage forms intended to meet the special needs of patients having difficulty
in swallowing (e.g.elderly, pediatric patients) and suffering from mental illness and developmental
disorders. Orodispersible films allow a more accurate dosing with respect to liquid dosage forms,
limiting errors in case of low-dose ingredients. Moreover, orodisperdible films presents the
unquestionable advantage to definitely eliminate the patient’s fear of chocking and, thus, to improve
compliance, with respect to the orodispersible tablets.
Malt-o-Fast films are generally administered without requiring water or chewing. Its main constituents
are a maltodextrin and glycerol; other additives or Pharmacopeia excipients can be added to the film
formulation to tailor the manufacturing requirements for a specific product (e.g., medicinals,
nutraceutics, etc). With a thickness range of 70 - 120 µm, Malt-o-Fast film dissolve within few
seconds. The maximum loading capacity is approximately 7-8 mg/cm2. The lack of hydrocolloids in
the formulation avoids the the unsmart sensation due to the swelling of the polymer. Malt-o-Fast films
can be produced either by hot-melt extrusion or solvent casting method and are individually packed..
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Malt-O-Fast: a platform to design orodispersible films
Speaker: Francesco Cilurzo
11 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi PlumeStars
NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
PlumeStars S.r.l.
www.plumestars.com
Startup
University of Parma
Strada Inzani 1,
43125 Parma (Italy)
Anna Giulia Balducci, [email protected]
PlumeStars is an innovative startup, located in Parma, specialized in manufacturing by “particle
engineering” of antibiotic powders for pulmonary administration to treat lung infections. In patients
affected by Cystic Fibrosis, Pseudomonas aeruginosa (PA) infection accelerates the lung tissue destruction
determining a respiratory failure. Recent treatment guidelines recommend the use of inhaled antibacterial
drugs against PA. Aerosolized antibiotics delivered to lung allow high drug concentrations while
minimizing systemic exposure and toxicity. PlumeStars is the exclusive licensee of a technology for
inhalation powders constructed using a very low amount of a lipophilic adjuvant (1% w/w). The technology
allows to obtain stable powders with elevated in vitro respirability. PlumeStars got the orphan designation
both from EMA (European Medicines Agency) and FDA (Food and Drug administration), for one
inhalation powder of amikacin.
Other antibiotics are in development such as tobramycin powder for inhalation. This last PlumeStars
product presents higher respirability and lower amount of excipients compared to the marketed competitor
(PlumeStars product 1%w/w, while the competitor 32 %w/w). As a result, the amount of powder to be
administered is significantly reduced. Therefore, using the DPI of Tobramycin PlumeStars the number of
capsules to inhale is lowered from 4 to 1. The compliance and convenience, in terms of adherence to the
therapy, of the patient is improved due to less side effects and shorter time administration.
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
SPEACH: Anna Giulia Balducci
Antibiotic dry powders for inhalation
12 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi s.r.l. NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
POLYMERIX
POLYMERIX
Start up innovativa
Università di Pavia
Via Taramelli, 24
27100 Pavia
Sofia Giorgetti ( 0382987783),
[email protected], [email protected]
POLYMERIX is an entrepreneurial project born from the scientific research expertises in the biochemistry,
biology, biotechnology and pharmaceutical areas developed within research groups of the University of
Pavia. The research in the different scientific fields is the unavoidable qualifying support to the
development of innovative health products with high technological content. The nucleus of academic
researchers in the biochemistry/biology/biotechnology/pharmaceutical areas is a strong point that makes the
entrepreneurial project attractive to: i) companies that wish to interact for products development and/or
patents, ii) Universities that wish to industrialize the results of their scientific research. POLYMERIX owns
technological platforms devoted both to structural and functional characterization of complex polymers of
natural and synthetic origin, and to design and develop innovative drug delivery systems and medical
devices. Our POLYMERIX is available as consulting firm in the characterization of complex matrices of
protein and polymer nature and in the design and development of new original materials which will be
directly used in tissue engineering, innovative diagnostic and drug delivery systems addressed to the high
socioeconomic impact diseases such as neurodegenerative diseases, diabetes, cancer, etc…
POLYMERIX offers services through MALDI TOF TOF as high technology analytical apparatus, and
electrospinning and Nanoassembler as manufacturing apparatuses.
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Innovation technology in Polymerix
Speaker: Enrica Chiesa
13 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi DEPARTMENT OF PHARMACY AND
BIOTECHNOLOGY
FaBiT
UNIVERSITY OF BOLOGNA
NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
Department of Pharmacy and Biotechnology – FaBiT
University of Bologna
http://www.fabit.unibo.it/it
NA
NA
Via S. Donato 15,
40127 Bologna (Italy)
Phone:+39 0512095613-email: [email protected]
The Department of Pharmacy and Biotechnology (FaBiT) of the University of Bologna is a
multidisciplinary Department currently comprises more than 150 people (including professors, post-doc
researchers and PhD students) active in a great variety of fields with an international level scientific
production.
In this multidisciplinary Department, the Pharmaceutical Technology and Drug Delivery research groups
carry out projects focused on the study of different dosage forms (micro-nanoparticles, inserts, films,
granules and tablets) for oral, buccal, nasal, vaginal and intravenous administration of molecules with
unfavorable biopharmaceutical properties.
Great attention is given to:
(1) rational development of the formulation strategies for optimizing drug delivery using natural and/or
GRAS excipients;
(2) choice of the suitable production technologies (spray-drying, spray-congealing, freeze-drying, film
casting, coacervation, wet and melt granulation and film-coating);
(3) evaluation of the technological and functional properties of the systems (morphology, particle size,
flowability, friability, drug loading, dissolution behaviors, swelling ability, mucoadhesion properties and
permeation across biological membranes);
(4) solid state characterization (DSC, XRD, FT-IR) of the produced delivery systems in order to correlate
their physicochemical properties to the technological and functional ones.
An interesting aspect of the research is the versatility of the developed delivery systems which can be
employed in pharmaceutical, cosmetic, herbal and food fields.
14 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi University of BONN
Pharmazeutische Technologie
NAME of the company or
institution
Web site
Type of society
In case of spin off, start Up,
center, refer the University
Address
Contacts (phone – fax - email)
Department of Pharmaceutics, University of Bonn
http://www.pharmazie.uni-bonn.de/www/pharmtech
University institute
Gerhard-Domagk-Str. 3
53121 Bonn - Germany
+49 228 73 5271, +49 228 73 5268, [email protected]
The research at the Pharmaceutics department of the University of Bonn is focused on the formulation and
process development, optimization, and delivery of low molecular weight drugs, peptides, and proteins by a
variety of technologies, including enabling formulations, extended release / depot drug delivery and
systems for drug delivery at absorptive barriers or gastroretentive systems, respectively.
Our main research projects focus on the development, characterization and prediction of:
• dispersed drug delivery systems, among them micro- and nanoparticles, microemulsions, selfemulsifying systems, and liposomes
• implants
• aerosols and dry powders for inhalation
• enabling formulations for oral delivery of poorly soluble drugs like:
o solid dispersions
o formulations enabled by functional excipients and/or process
o gastroretentive systems
Relevant biopharmaceutical tools to mimic drug transport are available for :
• oral delivery (cell culture systems)
• delivery to and across the skin (excised skin)
Target processes for which screening tools and production equipment is available:
• (Freeze) Spray drying
• Freeze drying
• Microencapsulation
• Hot-melt extrusion
• Wet-, dry- and melt-granulation
• Tableting
All formulation research is accompanied by state of the art analytical and material characterization tools.
Screening and prediction models (including numeric simulation) for most processes are available and/or
under evaluation.
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Drug targeting, enabling formulations and process improvement for
critical molecules and formulations.
Speaker: Alf Lamprecht
15 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi DEPARTMENT OF PHARMACEUTICAL
AND PHARMACOLOGICAL SCIENCES
UNIVERSITY OF PADOVA
NAME of the company or institution
Web site
Type of society
In case of spin off, start Up, center,
refer the University
Address
Contacts (phone – fax - email)
- Department of Pharmaceutical and Pharmacological Sciences
- Unired
- Ananas nanotech
http://www.dsfarm.unipd.it/dipartimento/presentazione
http://www.ananasnanotech.it/home/index.php
http://www.unired.it/en
Department of the University of Padova
UNIRED: spin-off, Srl
ANANAS Nanotech: spin-off
Department of Pharmaceutical and Pharmacological Sciences, University of Padova
Dept. of Pharmaceutical and Pharmacological Sciences and Ananas:
Via F. Marzolo 5 – 35131 Padova
Dep. of Pharmaceutical and Pharmacological Sciences,
Phone 049/8275326 Fax 049/8275366
Email [email protected]
ANANAS Nanotech: [email protected].
Unired Srl: [email protected]
The Department of Pharmaceutical and Pharmacological Sciences is recognized as reference centre for research and teaching focusing on drug
development.
Over the past decades, the Department has developed a variety of expertise including pharmaceutical chemistry and technology, pharmacology and
toxicology, integrated by solid experience in chemistry, biochemistry and cell biology, in addition to pharmaceutical and medical
bio/nanotechnology. The staff of the Department includes 60 researchers/professors, over 40 technicians and about 100 young researchers under
training (PhD students and post-doctoral fellows). In addition, the research laboratories host more than 100 undergraduated students performing
their experimental master project theses.
The research at the Department of Pharmaceutical and Pharmacological Sciences is focused on the development of novel approaches for drug
discovery by identifying new molecular targets, development of new pharmacotherapeutic agents and optimize new drug delivery systems, and
bioadhesive topical formulations. Moreover, breakthrough research in pharmaceutical biotechnology and in the regenerative processes of organs and
tissues are carried out with internationally recognized success. The Department relies on strong and integrated cooperation among the Department
components that participate in a variety of international research programs and projects.
Two Spin-off companies operate within the Department.
ANANAS Nanotech was founded in 2007 as a spin-off of the University of Padua. It is a company operating in the field of sensitive detection for in
vitro diagnostics. Currently it develops, manufactures and markets products and reagents for high sensitivity immunoassay that compete and
override present blockbuster reagents dedicated to high sensitivity immunodetection, within the majority of classic analytical platforms. ANANAS
Nanotech provides to IVD producers and developers, or research scientists its patented generic platform to help customers to implement their
reagents performance. Upon customer request, the company develops kits for the high sensitivity detection of specific analytes. Based on its
versatile proprietary nanoassembly technology, it can also provide multifunctionalyzed nanoasseblies according to customer requirements. The
ANANAS technology consists of an unique formulation of colloidal polyavidin nanoparticles. The nanoassembly is made of biocompatible
elements only, it is highly reproducible and has high stability in various buffers. The ANANAS technology is also currently under investigation as a
powerful and versatile drug delivery platform. The ANANAS IP is protected worldwide.
UNIRED is a spin-off of the University of Padova established to provide companies with problem solving, high scientific content, laboratories of
R&D, in the prospect of innovative growth and success. UNIRED offers products-services aimed at improving the formulation, evaluation of
perception, development of communication related to the product and to customers buying patterns.
UNIRED Srl is a spin-off company that focused on:
- Research and development of new cosmetic products, dietary and herbal food supplements, medical devices and household products;
- Market studies to derive customer satisfaction for product feedback aiming at the development, promotion and marketing of products for the
well-being;
- training initiatives aimed at qualification, specialization, updating and improvement of the company's staff.
UNIRED involves, also “Padova Resources Srl”, a spin-off of the University of Padova and Unifarco spa, cosmetic company specialized in
designing, manufacturing and marketing of cosmetic products and food supplements for the pharmacy stores.
Target: UNIRED intends to develop synergies between "academic" and "corporate" ways of thinking by decoding and integrating the strategies of
both parties to provide the end user customized solutions to operational problems and the supplier further guidance for advanced research.
16 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi DEPARTMENT OF DRUG CHEMISTRY
AND TECHNOLOGIES
UNIVERSITY SAPIENZA- ROMA
NAME of the company or
institution
Web site
Type of society
Address
Contacts (phone – fax - email)
Università Sapienza Università di Roma
www.uniroma1.it
University
p.le Aldo Moro 5, 00185, Roma, Italy
[email protected]
The presenters belong to the Department of Drug Chemistry and Technologies of the Sapienza University
of Roma, Italy.
Here are proposed some patents related to nanosystems useful for drug delivery applications.
One of the patents is related to the preparation of various nanobubble formulations from phospholipids and
surfactants. The patented nanobubbles can entrap, at the same time, UCAs and therapeutic agents and are
suitable for theranostic applications.
The other patents describe the preparation and the loading of nanohydrogels based on polysaccharide
matrices. The polysaccharides, previously derivatized with hydrophobic moieties, can form nanosystems by
an autoclave standard cycle treatment. The same treatment allows, in "a one pot step", the nanoparticle
loading with an appropriate hydrophobic and not thermo-labile drug..
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Nanohydrogels and Nanobubbles platforms for biomedical applications
Speakers: Pietro Matricardi and Carlotta Marianecci
17 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi DEPARTMENT OF DRUG SCIENCES
UNIVERSITY OF PAVIA
NAME of the company or
institution
University of Pavia, Department of Drug Sciences
Web site
Type of society
Address
Contacts (phone – fax - email)
http://dipsf.unipv.eu/site/home.html
NA
Viale Taramelli 12, 27100 Pavia
[email protected]
The department of Drug Sciences of the University of Pavia hosts three major research laboratories that are
challenged in different technological areas : pharmaceuticals, nutraceuticals, medical devices(MDs) and
testing methods thereof.
Each and every laboratory fosters innovation in specialized areas below.
Laboratory of Formulation Development and Technology (pharma section)
- polymeric and lipidic nanoparticles for ophthalmic and vaginal delivery
- in situ gelling systems for oral and colonic delivery
- polymeric micelles for improving drug solubility.
Laboratory of Formulation Development and Technology (Medical Device and testing section)
- polymeric scaffolds (sponge-like systems, nanofibers, nanocomposites, microparticles) for tissue repair
- In vitro assessment of mucoadhesive properties (tensile test, inclined plane test, washability test,
rheological synergism).
- In vitro assessment of drug penetration/permeation into/across animal model membranes and tissues.
- In vitro assessment of wound healing properties on model cell lines
- In vivo assessment of wound healing properties on murine model.
Laboratory of Food Chemistry and Nutraceutical Products
- Set up of new extraction and isolation methods of plant food bioactive components with antioxidant, antiinflammatory and antimicrobial activities.
- Chemical characterization of plant extracts through the determination of the main compounds (marker
compounds) or through the determination of finger print / blueprint using HPLC-MS analysis.
- Evaluation of the influence of simulated in vitro digestion process on nutraceutical product stability.
- In vitro determination (chemical and biological methods) of the antioxidant and anti-inflammatory
activities of plant food extracts.
- Patented technology for nanoemulsions based on chitosan salts as stabilizing agents (patent
MI2014A001812)
-Patented technological platform (including device) for mucosal delivery of hemoderivatives and
stabilization thereof (Biomed Device Srl (Reggello, FI, IT), patent US2011/0280952 A1)
- Natural products with nutritional and nutraceutical properties, isolated from plant foods (primary
agricultural products), and from waste products of coffee production, wine-making process, etc., to be used
in food supplements, and functional foods.
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Electrospun scaffolds based on condroitin sulfate/chitosan/pullulan
combinations for wound healing
Speaker: Giuseppina Sandri
18 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi DEPARTMENT OF PHARMACY
UNIVERSITY OF PISA
NAME of the company or
institution
Web site
Type of society
Address
Contacts (phone – fax - email)
DEPARTMENT OF PHARMACY – UNIVERSITY OF PISA
http://www.farm.unipi.it
Via Bonanno, 6 - 56126 Pisa
phone: +39 050 221 9500; fax: +39 050 2210680; [email protected]
The Department of Pharmacy of the University of Pisa was activated in 2012, as a result of the merging of the
Department of Pharmaceutical Sciences and of the Department of Psychiatry Neurobiology, Pharmacology and
Biotechnology.
The Department is composed of 33 professors and 22 assistant professors.The Prof.ssa Claudia Martini has been the
chair of the department from 2012. The Department of Pharmacy employs a workforce of more than 110 units
(including professors, researchers, technical and administrative people, post-doc fellows and PhD students).
The Department coordinates undergraduate programmes in Pharmacy and in Chemistry and Pharmaceutical
Technologies (Master Degrees),
and a bachelor degree in Science of Herbal Products and Health. Furthermore, the
Department coordinates a 2nd cycle degree in Science of Human Nutrition as graduate program (2 years), a Doctoral
Program (PhD) in Sciences of Drugs and Bioactive Substances and a Specialization Course in Hospital Pharmacy.
In this multidisciplinary department the research groups study Health Sciences, focusing on the different aspects of
drugs and bioactive natural products.
The researchers cover a broad spectrum of pharmaceutical sciences: Organic, Pharmaceutical, Computational and
Analytical Chemistry; Biochemistry; Molecular Biology; Physiology; Pharmacology; Phytochemistry and
Pharmaceutical technology. In this respect, the Dept. members carry out advanced research in: extraction,
characterization and purification of natural active substances, the design and synthesis of new molecules, the
biochemical characterization of drug mechanisms of action, and the optimization of drug delivery methods.
The main research projects in the Department are:
1) Design and development of new drugs and diagnostic substances useful for the treatment of inflammatory,
cardiovascular and degenerative diseases, tumor, metabolic and psychiatric disorders, also with the tool of new
synthetic methodologies regio- and stereo-selective;
2) Development of analytical methods in the pharmaceutical-toxicological, cosmetic, nutraceutical and phytochemical
sciences;
3) Synthesis, physico-chemical characterization and application of ionic liquids for the development of
environmentally sustainable chemical processes or new materials;
4) Synthesis of glycoconjugates with high biological value;
5) Design, preparation and characterization of innovative pharmaceutical formulations for ophthalmologic, skin, nail
and mucosal administration, and their evaluation in vitro and in vivo;
6) Synthesis and characterization of chitosan derivatives for the preparation of nanosystems suitable for ophthalmic
administration and oral medications or nutraceuticals;
7) Extraction, isolation and characterization of volatile and non-volatile secondary metabolites from medicinal and
food plants of spontaneous origin, cultivated and / or micropropagated. Study of their biofarmacologica activities;
8) Morpho-functional study in in vivo and in vitro animal models of retinal degenerative diseases for the development
of novel therapeutic approaches;
9) Proteomic analysis for the identification of biomarkers and molecular mechanisms involved in pathological
processes;
10) Receptor, signaling and regulation of metabolism in differentiation and cell life/death processes in
pathophysiological states;
11) Study of potassium channels and gas-transmitters in regulation of cardiovascular function;
12) Pharmacological modulation of inflammatory diseses of the respiratory tract;
13) Evaluation of new therapeutic strategies, including technological, and genomic and non-genomic markers in
toxicology.
TITLE of PRESENTATION
Connecting Universities
PharmaWeek Room
Technological approaches for overcoming formulation challenges in ocular
delivery
Speaker: Patrizia Chetoni
19 AREA INNOVAZIONE E FORMAZIONE Hall: Centro servizi CONNECTING UNIVERSITIES
Universities, Start-up and Spin-off show their technological innovations to the industry
PharmaWeek Room - Centro Servizi
Wednesday 13th, April 2016
Time: 13:30 – 15:00
13:30 – 13:45
TEFARCO Innova
Consorzio Interuniversitario Nazionale di Tecnologie Farmaceutiche
Innovative – TEFARCO Innova
Speaker: Paolo Colombo
BIOPHARMANET TEC – Leading Innovation in Pharma
Speaker: Fabio Sonvico
13:45 – 14:00
BIOPHARMANET-TEC
14:00 – 14:15
AQUILON
PHARMACEUTICALS Ulg
Innovative solutions for the treatment of respiratory diseases
Speaker: Paul Maes
14:15 – 14:30
Università di SIENA
Dip.to Farmacia
14:30 – 14:45
ETICHUB
Technological approaches for overcoming formulation challenges in
ocular delivery
Speaker: Patrizia Chetoni
Take care of your idea, built your cosmetic product
Speaker: Camilla Grignani
14:45 – 15:00
PHARMAFILM
Malt-O-Fast: a platform to design orodispersible films
Speaker: Francesco Cilurzo
Thusday 14th , April 2016
Time: 15:30 – 17:15 15:30 – 15:45
PLUME STARS
Antibiotic dry powders for inhalation
Speaker: Anna Giulia Balducci
15:45 – 16:00
POLYMERIX
Innovation technology in Polymerix
Speaker: Enrica Chiesa
16:00 – 16:15
CHT Center for Health
Technologies
Centre for Health Technology
Speaker: Bice Conti
16:15 – 16:30
University of BONN
Pharmazeutische Technologie
16:30 – 16:45
Università di ROMA LA
SAPIENZA
Dipartimento di Chimica e
Tecnologia del Farmaco
Università di PAVIA
Department of Drug Sciences
Drug targeting, enabling formulations and process improvement for
critical molecules and formulations.
Speaker: Alf Lamprecht
Nanohydrogels and Nanobubbles platforms for biomedical
applications
Speakers: Pietro Matricardi and Carlotta Marianecci
16:45 – 17:00
17:00 – 17:15
DOME MATRIX
Electrospun scaffolds based on condroitin sulfate/chitosan/pullulan
combinations for wound healing
Speaker: Giuseppina Sandri
Dome Matrix
Speaker: Giulia Pasotti
Per informazioni contattare Dr.ssa Elena Vidale ([email protected] )
20